金沙检测线路js95(中国)股份有限公司-Official website

Disease & Solutions Products Professional Education Innovation Ecosystem Investor Relations News Careers About Us
You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
Milestones
Corporate Overview Milestones Leadership Team Corporate Social Responsibility Awards and Recognitions Contact Us
2021
2022-05-23 13:58:59

The Company obtained NMPA's approval for TaurusOne® and TaurusElite®.

The Company started a multi-center clinical trial of the TaurusNXT® Transcatheter Aortic Valve Replacement System.

The Company completed the enrollment of the first subject for the First-in-human clinical trial of the TaurusWave®  Lithotripsy Valvuloplasty System.

The Company signed a cooperation development agreement with the U.S. company inQB8 Medical Technologies for transcatheter tricuspid valve replacements (TTVR).

The Company obtained NMPA's approval for Jasper® SS Intracranial Electrolytic Detachable Coil.、

The Company's Global Headquarters Base settled in Suzhou Industrial Park.



Prev：2020
Next：2013
Top
XML 地图